189 related articles for article (PubMed ID: 31600833)
1. Efficacy and safety of basic fibroblast growth factor (bFGF) related decapeptide solution plus Tacrolimus 0.1% ointment versus Tacrolimus 0.1% ointment in the treatment of stable vitiligo.
Shah B; Godse K; Mahajan S; Grandhi S; Shendkar S; Sharma A; Teli C; Pathak R; Parsad D
Dermatol Ther; 2019 Nov; 32(6):e13109. PubMed ID: 31600833
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety Comparison of Basic Fibroblast Growth Factor-Related Decapeptide 0.1% Solution (bFGFrP) Plus Oral PUVA Combination Therapy with Oral PUVA Monotherapy in the Treatment of Vitiligo.
Nayak CS; Kura MM; Banerjee G; Patil SP; Deshpande A; Sekar S; Sharma A; Pathak R; Sarma P
J Cutan Aesthet Surg; 2023; 16(1):28-33. PubMed ID: 37383981
[TBL] [Abstract][Full Text] [Related]
3. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo.
Passeron T; Ostovari N; Zakaria W; Fontas E; Larrouy JC; Lacour JP; Ortonne JP
Arch Dermatol; 2004 Sep; 140(9):1065-9. PubMed ID: 15381545
[TBL] [Abstract][Full Text] [Related]
4. Vitiligo treatment with monochromatic excimer light and tacrolimus: results of an open randomized controlled study.
Nisticò S; Chiricozzi A; Saraceno R; Schipani C; Chimenti S
Photomed Laser Surg; 2012 Jan; 30(1):26-30. PubMed ID: 22054204
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo.
Lo YH; Cheng GS; Huang CC; Chang WY; Wu CS
J Dermatol; 2010 Feb; 37(2):125-9. PubMed ID: 20175845
[TBL] [Abstract][Full Text] [Related]
6. Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study.
Majid I
Photodermatol Photoimmunol Photomed; 2010 Oct; 26(5):230-4. PubMed ID: 20831696
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled Study.
Seneschal J; Duplaine A; Maillard H; Passeron T; Andreu N; Lassalle R; Favary C; Droitcourt C; Taïeb A; Ezzedine K
J Invest Dermatol; 2021 Jul; 141(7):1728-1734. PubMed ID: 33549606
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of 308-nm Excimer lamp combined with Tacrolimus 0.1% ointment vs Tacrolimus 0.1% ointment as monotherapy in treating children with limited vitiligo: a randomized controlled trial.
Alshiyab D; Ba-Shammakh SA; Al-Fakih A; Tashman O; Sarakbi D; Al-Qarqaz F; Muhaidat J; Atwan A; Cork MJ
J Dermatolog Treat; 2024 Dec; 35(1):2296851. PubMed ID: 38124534
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series.
Tanghetti EA
Cutis; 2003 Feb; 71(2):158-62. PubMed ID: 12635898
[TBL] [Abstract][Full Text] [Related]
10. Microdermabrasion and topical tacrolimus: A novel combination therapy of vitiligo.
Abd-Elazim NE; Yassa HA; Mahran AM
J Cosmet Dermatol; 2020 Jun; 19(6):1447-1455. PubMed ID: 31668003
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Childhood Vitiligo Using Tacrolimus Ointment with Narrowband Ultraviolet B Phototherapy.
Dayal S; Sahu P; Gupta N
Pediatr Dermatol; 2016 Nov; 33(6):646-651. PubMed ID: 27699846
[TBL] [Abstract][Full Text] [Related]
12. Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-month prospective study.
Hartmann A; Bröcker EB; Hamm H
Acta Derm Venereol; 2008; 88(5):474-9. PubMed ID: 18779885
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review.
Sisti A; Sisti G; Oranges CM
An Bras Dermatol; 2016 Apr; 91(2):187-95. PubMed ID: 27192518
[TBL] [Abstract][Full Text] [Related]
14. Treatment of vitiligo with narrowband-UVB (TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right/left double-blind comparative study.
Nordal EJ; Guleng GE; Rönnevig JR
J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1440-3. PubMed ID: 21466589
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0·1% vs. clobetasol propionate 0·05% in childhood vitiligo.
Ho N; Pope E; Weinstein M; Greenberg S; Webster C; Krafchik BR
Br J Dermatol; 2011 Sep; 165(3):626-32. PubMed ID: 21457214
[TBL] [Abstract][Full Text] [Related]
16. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo.
Lan CC; Chen GS; Chiou MH; Wu CS; Chang CH; Yu HS
Br J Dermatol; 2005 Sep; 153(3):498-505. PubMed ID: 16120133
[TBL] [Abstract][Full Text] [Related]
17. Vitiligo, NB-UVB and tacrolimus: our experience in Naples.
Baldo A; Lodi G; Di Caterino P; Monfrecola G
G Ital Dermatol Venereol; 2014 Feb; 149(1):123-30. PubMed ID: 24566573
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo.
Xu AE; Zhang DM; Wei XD; Huang B; Lu LJ
Int J Dermatol; 2009 Jan; 48(1):86-90. PubMed ID: 19126059
[TBL] [Abstract][Full Text] [Related]
19. Topical Tacrolimus Ointment Alone versus in Combination with Microneedling for Refractory Stable Vitiligo.
Kiran A; Khan S; Ahmed N; Ali M
J Coll Physicians Surg Pak; 2024 May; 34(5):514-517. PubMed ID: 38720208
[TBL] [Abstract][Full Text] [Related]
20. Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients.
Fai D; Cassano N; Vena GA
J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):916-20. PubMed ID: 17659000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
